Dark Light

Follow
- New Adventures with Innovation Toronto
  
  Innovation Toronto has been running since 2007 and as such is getting a little old in terms of its constituent parts. the theme in particular has been a problem mainly because we relied too much on some of the components attached to it and therefore could not move on without extensive work. it is now come to the point where that extensive work is going to produce good results. we are already in the process of updating and upgrading various parts of it and over time will make sure that each and every post has been Revisited and revamped so it presents as best it can.
  
  Testing

Dark Light

Follow
- New Adventures with Innovation Toronto
  
  Innovation Toronto has been running since 2007 and as such is getting a little old in terms of its constituent parts. the theme in particular has been a problem mainly because we relied too much on some of the components attached to it and therefore could not move on without extensive work. it is now come to the point where that extensive work is going to produce good results. we are already in the process of updating and upgrading various parts of it and over time will make sure that each and every post has been Revisited and revamped so it presents as best it can.
  
  Testing

ML901

Diagrammatic representation of the target of the antimalarial compound ML901 (coloured structure), showing highly specific and potent inhibition of the malaria parasite. ML901 finds a particular chink in an enzyme called tyrosine tRNA synthetase (depicted in pink), part of the machinery that the malaria parasite uses to generate the proteins needed to reproduce itself. The parasite rapidly grinds to a halt and can’t cause disease or be transmitted to other people via mosquitoes (purple). Image: Leann Tilley and Riley Metcalfe

A new weapon against drug-resistant malaria: This parasite will self-destruct